-
Loading metrics
Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy
- Caroline Schmidbauer,
- Michael Schwarz,
- Angelika Schütz,
- Raphael Schubert,
- Cornelia Schwanke,
- Enisa Gutic,
- Roxana Pirker,
- Tobias Lang,
- Thomas Reiberger,
- Hans Haltmayer
x
- Published: June 4, 2021
- https://doi.org/10.1371/journal.pone.0252274